Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Trials & Approvals

Updates on new clinical tirals being performed in China, trial updates and drug approvals...

BioCity Plans Trial of TIM-3 mAb with AstraZeneca’s PD-L1 for Liver Cancer

AffaMed Approved to Begin China Phase III Trial of Candidate for Dry AMD

RemeGen Says Dual Targeted B-Cell Drug Meets Endpoints for Rheumatoid Arthritis

Gracell Reports 100% Minimal Residual Disease Rate for CAR-T in Myeloma Trial

Ascletis Enrolls 120 Patients for Phase III Trial of Glioblastoma Candidate

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China